KIT and colorectal carcinoma: Activating oncogenic mutations of BRAF have been described in many malignancies, including cutaneous melanoma (67%), colorectal carcinoma (12%), non-small cell lung carcinoma (NSCLC; 3%), and KIT wild-type GIST (13%)[5,17].